Evidence map›Paper›PMID 35605816›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2022

A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies.

Kristen B Corey, Grace Koo, Cosby A Stone, Susan F Kroop, William H Fissell, Steven Kozlowski, Zhao-Hua Zhou, Elizabeth J Phillips

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kristen B CoreyDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Grace KooDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Cosby A StoneDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Susan F KroopDivision of Rheumatology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
William H FissellDivision of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Steven KozlowskiOffice of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Zhao-Hua ZhouOffice of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Elizabeth J PhillipsDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, Australia. Electronic address: elizabeth.j.phillips@vanderbilt.edu.
Vanderbilt University Medical Center · USCenter for Drug Evaluation and Research · USMurdoch University · AU

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5M
Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1M
Learning Health System Scholar Program at VanderbiltK12HS026395 · AHRQ · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROTHMAN, RUSSELL L., ROUMIE, CHRISTIANNE L. · 2018 to 2022
$2.7M
Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6M
Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and CommunityR13AR078623 · NIAMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2021 to 2021
$33k
AHRQ HHS K12 HS026395NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAID NIH HHS UM1 AI109565NIAMS NIH HHS R13 AR078623
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesPolyethylene GlycolsAntibodiesHumansImmunitymRNA VaccinesRNA, MessengerVaccines, SyntheticAntibodiesCOVID-19 VaccinesmRNA VaccinesPolyethylene GlycolsRNA, MessengerVaccines, Synthetic

Identifiers

PMID35605816
PMCPMC9181833
OpenAlexW4282937624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.